Table 1 Hematologic cancers with clinically applied drug sensitivity protocols.
From: Standardized assays to monitor drug sensitivity in hematologic cancers
Cancer type | Drug sensitivity read-out | Pre-clinical/clinical application | Reference |
|---|---|---|---|
Aggressive hematologic malignancies | Single-cell image analysis | Screen 143 patients, guide treatment of 56 patients (39%) (EXALT trial) | NCT03096821 [4] |
Aggressive hematologic malignancies | Single-cell image analysis | EXALT-2 trial | NCT04470947 |
AML | CellTiter-Glo | Screen 187 patients, guide treatment of 37 patients (20%) | [5] |
AML | Flow cytometry | VenEx trial | NCT04267081 [19] |
AML | Flow cytometry | LD-VenEx trial | NCT05431257 |
CLL | CellTiter-Glo | Method development and application to guide treatment of an R/R patient | [8] |
CLL | CellTiter-Glo | Application to guide treatment of an R/R patient | [6] |
CLL | CellTiter-Glo | IMPRESS-Norway trial | NCT04817956 |
